Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms

PHASE2CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

May 31, 2006

Conditions
Overactive Bladder
Interventions
DRUG

Solabegron

Trial Locations (66)

112

GSK Investigational Site, Taipei

404

GSK Investigational Site, Taichung

970

GSK Investigational Site, Hualien City

1000

GSK Investigational Site, Ljubljana

1120

GSK Investigational Site, Av Córdoba 2424

2031

GSK Investigational Site, Randwick

2380

GSK Investigational Site, Slovenj Gradec

3000

GSK Investigational Site, Celje

3053

GSK Investigational Site, Carlton

3140

GSK Investigational Site, Tauranga

4000

GSK Investigational Site, Spring Hill

4021

GSK Investigational Site, Kippa-Ring

4510

GSK Investigational Site, Caboolture

5000

GSK Investigational Site, Córdoba

5016

GSK Investigational Site, Córdoba

7130

GSK Investigational Site, Somerset West

8001

GSK Investigational Site, Bahía Blanca

GSK Investigational Site, Cape Town

8014

GSK Investigational Site, Christchurch

9016

GSK Investigational Site, Dunedin

9300

GSK Investigational Site, Bloemfontein

10787

GSK Investigational Site, Berlin

13125

GSK Investigational Site, Berlin

16303

GSK Investigational Site, Schwedt

18012

GSK Investigational Site, Granada

19230

GSK Investigational Site, Hagenow

20014

GSK Investigational Site, Donostia / San Sebastian

20249

GSK Investigational Site, Hamburg

22143

GSK Investigational Site, Hamburg

28905

GSK Investigational Site, Getafe

29600

GSK Investigational Site, Marbella

30211

GSK Investigational Site, Vigo (Pontevedra)

33521

GSK Investigational Site, Tampere

35039

GSK Investigational Site, Marburg

39112

GSK Investigational Site, Magdeburg

46009

GSK Investigational Site, Valencia

46010

GSK Investigational Site, Valencia

69230

GSK Investigational Site, Saint-Genis-Laval

69437

GSK Investigational Site, Lyon

75571

GSK Investigational Site, Paris

75970

GSK Investigational Site, Paris

90100

GSK Investigational Site, Oulu

92151

GSK Investigational Site, Suresnes

C1406CPC

GSK Investigational Site, Ciudad Autonoma de Buenos Aires

C1425BGV

GSK Investigational Site, Ciudad de Buenos Aires

C1113AAH

GSK Investigational Site, Buenos Aires

01307

GSK Investigational Site, Dresden

04109

GSK Investigational Site, Leipzg

04103

GSK Investigational Site, Leipzig

04105

GSK Investigational Site, Leipzig

06844

GSK Investigational Site, Dessau

LV 1002

GSK Investigational Site, Riga

7314 ET

GSK Investigational Site, Apeldoorn

7824 AA

GSK Investigational Site, Emmen

7511JX

GSK Investigational Site, Enschede

6525 GA

GSK Investigational Site, Nijmegen

5022 GC

GSK Investigational Site, Tilburg

3584 CJ

GSK Investigational Site, Utrecht

0112

GSK Investigational Site, Whangarei

90-710

GSK Investigational Site, Lodz

20-954

GSK Investigational Site, Lublin

120-752

GSK Investigational Site, Seoul

135-710

GSK Investigational Site, Seoul

137-701

GSK Investigational Site, Seoul

138-736

GSK Investigational Site, Seoul

08035

GSK Investigational Site, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY